LOS ANGELES--(BUSINESS WIRE)--SiDMAP, LLC, a provider of metabolic profiling and biomarker development services to the pharmaceutical and biotechnology industries, announced today the discovery of an early metabolic marker for liver toxicity linked to the drug valproic acid, which is used in the treatment of epilepsy, bi-polar disease, and other disorders of the central nervous system. The new biomarker was discovered jointly by SiDMAP scientists and their scientific collaborators at the U.S. Food and Drug Administration (FDA).
